Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Magnesium trisilicate suspension is an oral antacid formulation used for the symptomatic relief of gastrointestinal conditions associated with hyperacidity, such as heartburn, acid indigestion, and dyspepsia. The active ingredient, magnesium trisilicate, is an inorganic salt that reacts with gastric hydrochloric acid to form magnesium chloride and hydrated silica. This reaction neutralizes stomach acid, thereby increasing the pH of the gastric contents. Additionally, the hydrated silica produced in the reaction can form a protective gel-like layer over the gastric mucosa and may adsorb pepsin, providing further relief in conditions like peptic ulcer disease and gastroesophageal reflux disease (GERD). It is marketed as a branded generic by companies such as Fidson HealthCare.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on magnesium trisilicate suspension.